🔬 IMMUcan at #ESMOImmuno25 | Poster Highlight II
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
December 18, 2025 at 10:57 AM
🔬 IMMUcan at #ESMOImmuno25 | Poster Highlight II
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
Real-world data from early-stage #TNBC show evolving neoadjuvant practice across Europe:
⬇️ anthracyclines
⬆️ carboplatin & immunotherapy
📈 pCR rates, highest with KEYNOTE-522–like regimens and high TIL tumors
👉 www.immucan.eu
📣 All #ESMOImmuno25 congress sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
December 16, 2025 at 4:30 PM
📣 All #ESMOImmuno25 congress sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
👉 Watch on demand and stay at the forefront of oncology. #esmomeetings
🔗 https://ow.ly/7MwC50XHrLB
🔬 IMMUcan at #ESMOImmuno25
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
December 16, 2025 at 10:07 AM
🔬 IMMUcan at #ESMOImmuno25
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
New multi-omics data from advanced TNBC patients treated with chemo-immunotherapy (SYNERGY & EORTC-1553-SPECTA) highlight how early tumor microenvironment changes shape outcomes.
Recent #ESMOImmuno25 was great! @myesmo.bsky.social
🔥Was a pleasure to present our #AI #multiomics #spatial #immunology guided #reverse #translation work in #clinical #colorectalcancer context+reveal our #RETROFIT platform for #nextgeneration #immunotherapy creation!
@kuleuvenuniversity.bsky.social
🔥Was a pleasure to present our #AI #multiomics #spatial #immunology guided #reverse #translation work in #clinical #colorectalcancer context+reveal our #RETROFIT platform for #nextgeneration #immunotherapy creation!
@kuleuvenuniversity.bsky.social
December 15, 2025 at 9:46 AM
Recent #ESMOImmuno25 was great! @myesmo.bsky.social
🔥Was a pleasure to present our #AI #multiomics #spatial #immunology guided #reverse #translation work in #clinical #colorectalcancer context+reveal our #RETROFIT platform for #nextgeneration #immunotherapy creation!
@kuleuvenuniversity.bsky.social
🔥Was a pleasure to present our #AI #multiomics #spatial #immunology guided #reverse #translation work in #clinical #colorectalcancer context+reveal our #RETROFIT platform for #nextgeneration #immunotherapy creation!
@kuleuvenuniversity.bsky.social
The groundbreaking work behind the development of TCR mimics − ‘minibinders’ − is described by Sine Reker Hadrup in her Keynote Lecture at #ESMOImmuno25 and in an Opinion piece in the #ESMODailyReporter #ImmunoOncology
👉 https://ow.ly/jH9x50XHyFI
👉 https://ow.ly/jH9x50XHyFI
December 12, 2025 at 10:20 AM
The groundbreaking work behind the development of TCR mimics − ‘minibinders’ − is described by Sine Reker Hadrup in her Keynote Lecture at #ESMOImmuno25 and in an Opinion piece in the #ESMODailyReporter #ImmunoOncology
👉 https://ow.ly/jH9x50XHyFI
👉 https://ow.ly/jH9x50XHyFI
Jean-Philippe Spano presents, "Survival outcomes in POD1UM-303/InterAACT-2: A phase III study of retifanlimab (R) + carboplatin-paclitaxel (CP) in first-line (1L) advanced squamous anal cancer (SCAC)” at #ESMOImmuno25.
December 11, 2025 at 3:01 PM
Jean-Philippe Spano presents, "Survival outcomes in POD1UM-303/InterAACT-2: A phase III study of retifanlimab (R) + carboplatin-paclitaxel (CP) in first-line (1L) advanced squamous anal cancer (SCAC)” at #ESMOImmuno25.
#ESMOImmuno25: Mature overall survival data from the phase III POD1UM-303/InterAACT-2 #ClinicalTrial confirm the benefits of retifanlimab plus chemotherapy in the treatment of advanced squamous cell #AnalCancer.
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL
December 11, 2025 at 2:30 PM
#ESMOImmuno25: Mature overall survival data from the phase III POD1UM-303/InterAACT-2 #ClinicalTrial confirm the benefits of retifanlimab plus chemotherapy in the treatment of advanced squamous cell #AnalCancer.
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL
Read more #ESMODailyReporter ➡️ https://ow.ly/rPN850XHmSL
As Fangling Ning presents data on SIRpα-fc fusion protein at #ESMOImmuno25, address blockade of CD47 with this recent #JITC article from Chilam Chan et al of UMC Utrecht: https://ow.ly/lbJV50XH7A5
December 11, 2025 at 2:02 PM
As Fangling Ning presents data on SIRpα-fc fusion protein at #ESMOImmuno25, address blockade of CD47 with this recent #JITC article from Chilam Chan et al of UMC Utrecht: https://ow.ly/lbJV50XH7A5
#ESMOImmuno25: The next-generation PRAME-directed TCR T-cell therapy, IMA203CD8, showed encouraging activity not only in melanoma, but also in #OvarianCarcinoma and synovial sarcoma in a phase I #ClinicalTrial. Find out more in the #ESMODailyReporter ➡️ https://ow.ly/m30F50XHmHM
December 11, 2025 at 1:10 PM
#ESMOImmuno25: The next-generation PRAME-directed TCR T-cell therapy, IMA203CD8, showed encouraging activity not only in melanoma, but also in #OvarianCarcinoma and synovial sarcoma in a phase I #ClinicalTrial. Find out more in the #ESMODailyReporter ➡️ https://ow.ly/m30F50XHmHM
#ICYMI: At #ESMOImmuno25, Antonia Busse presented, “A phase I trial of IMA203CD8, a PRAME-directed TCR T cell therapy in PRAME-positive solid tumors”.
December 11, 2025 at 1:00 PM
#ICYMI: At #ESMOImmuno25, Antonia Busse presented, “A phase I trial of IMA203CD8, a PRAME-directed TCR T cell therapy in PRAME-positive solid tumors”.
#ESMOImmuno25: Encouraging data reported with the PD-L1/TGF-β-targeting bifunctional fusion protein, SHR-1701, added to first-line CAPOX in an analysis of patients with #GastricCancer and high-risk features. More info in the #ESMODailyReporter ➡️ https://ow.ly/WF1450XHmqY
December 11, 2025 at 12:30 PM
#ESMOImmuno25: Encouraging data reported with the PD-L1/TGF-β-targeting bifunctional fusion protein, SHR-1701, added to first-line CAPOX in an analysis of patients with #GastricCancer and high-risk features. More info in the #ESMODailyReporter ➡️ https://ow.ly/WF1450XHmqY
Cellular therapies have changed #Immunooncology (IO) dramatically but their clinical and technical challenges in remain. Marco Donia (DK) elegantly summarized the developments and puts cutting-edge strategies on show at #esmoimmuno25 in London. Careful patient […]
[Original post on mstdn.science]
[Original post on mstdn.science]
December 11, 2025 at 10:41 AM
Cellular therapies have changed #Immunooncology (IO) dramatically but their clinical and technical challenges in remain. Marco Donia (DK) elegantly summarized the developments and puts cutting-edge strategies on show at #esmoimmuno25 in London. Careful patient […]
[Original post on mstdn.science]
[Original post on mstdn.science]
At #ESMOImmuno25, Hans Nijman reports how “Neoadjuvant immune checkpoint inhibition skews the B cell response in mismatch repair deficient endometrial cancer”.
December 10, 2025 at 6:02 PM
At #ESMOImmuno25, Hans Nijman reports how “Neoadjuvant immune checkpoint inhibition skews the B cell response in mismatch repair deficient endometrial cancer”.
As Dimitrios A. Garyfallos shares new findings on, “In vivo CRISPR/Cas9 genetic screens identify novel immunotherapy target” at #ESMOImmuno25, discover more on CRISPR with #JITC!
December 10, 2025 at 5:30 PM
As Dimitrios A. Garyfallos shares new findings on, “In vivo CRISPR/Cas9 genetic screens identify novel immunotherapy target” at #ESMOImmuno25, discover more on CRISPR with #JITC!
'Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity'
Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇
Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇
#ESMODailyReporter: Jon Lim, MRCP PhD discusses the use of single-cell spatial transcriptomics and proteomic profiling to dissect why #immunotherapy works in some tumours but not others, highlighting neoadjuvant studies at #ESMOImmuno25 #ImmunoOncology
➡️ https://ow.ly/kwgt50XGX4M
➡️ https://ow.ly/kwgt50XGX4M
December 10, 2025 at 5:07 PM
'Neoadjuvant immunotherapy continues to rewrite our understanding of anticancer immunity'
Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇
Check out my #ESMODailyReporter editorial on some of the abstracts presented at this year's #ESMOImmuno25 in London 👇
✨ #ESMOImmuno25
@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.
The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.
@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.
The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.
December 10, 2025 at 4:58 PM
✨ #ESMOImmuno25
@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.
The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.
@turajliclab.bsky.social presented the MANIFEST platform, recent progress & our ambitions at ESMO IO Congress here in London.
The message from the 'Special Session with Industry': cross-sector collaboration is critical to accelerate discovery & develop safer/effective therapies.
Exciting science unfolding at #ESMOImmuno25! Today’s oral abstract session featured Andreas Pircher’s presentation on, “Neoadjuvant induction with pembrolizumab (Pembro) plus lenvatinib (Len) in resectable early-stage NSCLC impacts the tumor microenvironment (TME)."
December 10, 2025 at 4:26 PM
Exciting science unfolding at #ESMOImmuno25! Today’s oral abstract session featured Andreas Pircher’s presentation on, “Neoadjuvant induction with pembrolizumab (Pembro) plus lenvatinib (Len) in resectable early-stage NSCLC impacts the tumor microenvironment (TME)."
#ESMODailyReporter: Jon Lim, MRCP PhD discusses the use of single-cell spatial transcriptomics and proteomic profiling to dissect why #immunotherapy works in some tumours but not others, highlighting neoadjuvant studies at #ESMOImmuno25 #ImmunoOncology
➡️ https://ow.ly/kwgt50XGX4M
➡️ https://ow.ly/kwgt50XGX4M
December 10, 2025 at 4:12 PM
#ESMODailyReporter: Jon Lim, MRCP PhD discusses the use of single-cell spatial transcriptomics and proteomic profiling to dissect why #immunotherapy works in some tumours but not others, highlighting neoadjuvant studies at #ESMOImmuno25 #ImmunoOncology
➡️ https://ow.ly/kwgt50XGX4M
➡️ https://ow.ly/kwgt50XGX4M
#ESMOImmuno25 Awardee, Ignacio Melero, discusses how current #immunotherapy can be improved upon with the use of synergistic approaches including combination therapies and targeting resistance mechanisms. Full interview in the #ESMODailyReporter 👉 https://ow.ly/bgun50XGRUt
December 10, 2025 at 2:32 PM
#ESMOImmuno25 Awardee, Ignacio Melero, discusses how current #immunotherapy can be improved upon with the use of synergistic approaches including combination therapies and targeting resistance mechanisms. Full interview in the #ESMODailyReporter 👉 https://ow.ly/bgun50XGRUt
Great pleasure to be part of European Society for Medical Oncology Immunooncology meeting in London #esmoimmuno25 as a scientific committee member, chair and invited speaker. The first day already kicks off with brilliant talks on tertiary lymphoid structures […]
[Original post on mstdn.science]
[Original post on mstdn.science]
December 10, 2025 at 1:39 PM
Great pleasure to be part of European Society for Medical Oncology Immunooncology meeting in London #esmoimmuno25 as a scientific committee member, chair and invited speaker. The first day already kicks off with brilliant talks on tertiary lymphoid structures […]
[Original post on mstdn.science]
[Original post on mstdn.science]
👉 #ESMOImmuno25: A. Marabelle, I.M. Svane and S. Quezada welcome you to the ESMO Immuno-Oncology Congress 2025, an international event to explore the science driving the next generation of cancer care.
#esmomeetings
🔗 buff.ly/jCNSjtl
#esmomeetings
🔗 buff.ly/jCNSjtl
December 10, 2025 at 11:15 AM
👉 #ESMOImmuno25: A. Marabelle, I.M. Svane and S. Quezada welcome you to the ESMO Immuno-Oncology Congress 2025, an international event to explore the science driving the next generation of cancer care.
#esmomeetings
🔗 buff.ly/jCNSjtl
#esmomeetings
🔗 buff.ly/jCNSjtl
Really looking forward to catching up with colleagues and friends at #ESMOImmuno25 in London.
If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.
If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.
December 9, 2025 at 1:54 PM
Really looking forward to catching up with colleagues and friends at #ESMOImmuno25 in London.
If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.
If you’re attending, please stop by our team’s poster - presented by our Specialist Pharmacist Ragini Jethra. We highlight new insights from our systematic review on the safety profile of TIL therapy.
We will be at ESMO IO talking about our T cell engager (TCE) platform and CDR404, our novel, bispecific and bivalent antibody-derived TCE that targets MAGE-A4. Don’t miss our Phase 1 poster: #ESMOImmuno25
December 4, 2025 at 1:54 PM
We will be at ESMO IO talking about our T cell engager (TCE) platform and CDR404, our novel, bispecific and bivalent antibody-derived TCE that targets MAGE-A4. Don’t miss our Phase 1 poster: #ESMOImmuno25
📣 #ESMOImmuno25: A. Marabelle, I.M. Svane and S. Quezada unveil some highlights of this unmissable event.
⏰ Register by 12 November and benefit from advantageous fees. #esmomeetings
🔗 https://ow.ly/wNZT50XpsJ0
⏰ Register by 12 November and benefit from advantageous fees. #esmomeetings
🔗 https://ow.ly/wNZT50XpsJ0
November 11, 2025 at 9:40 AM
📣 #ESMOImmuno25: A. Marabelle, I.M. Svane and S. Quezada unveil some highlights of this unmissable event.
⏰ Register by 12 November and benefit from advantageous fees. #esmomeetings
🔗 https://ow.ly/wNZT50XpsJ0
⏰ Register by 12 November and benefit from advantageous fees. #esmomeetings
🔗 https://ow.ly/wNZT50XpsJ0
📣 #ESMOImmuno25: Your not-to-miss sessions! Scientific advances in clinical focus, featuring discussions on monitoring side effects in patients undergoing immunotherapy and more!
⏰ Register by 12 November and benefit from advantageous fees. #esmomeetings
🔗 https://ow.ly/7olu50XeT0W
⏰ Register by 12 November and benefit from advantageous fees. #esmomeetings
🔗 https://ow.ly/7olu50XeT0W
November 5, 2025 at 10:00 AM
📣 #ESMOImmuno25: Your not-to-miss sessions! Scientific advances in clinical focus, featuring discussions on monitoring side effects in patients undergoing immunotherapy and more!
⏰ Register by 12 November and benefit from advantageous fees. #esmomeetings
🔗 https://ow.ly/7olu50XeT0W
⏰ Register by 12 November and benefit from advantageous fees. #esmomeetings
🔗 https://ow.ly/7olu50XeT0W